1-[(6-chloronaphthalen-2-yl)sulfonyl]-4-[4-(pyridin-4-yl)benzoyl]piperazine | 207798-71-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[(6-chloronaphthalen-2-yl)sulfonyl]-4-[4-(pyridin-4-yl)benzoyl]piperazine
• 英文别名: 1-(6-chloronaphth-2-ylsulphonyl)-4-[4-(4-pyridinyl)benzoyl]piperazine；1-(6-chloronaphthalene-2-sulfonyl)-4-[4-(4-pyridyl)benzoyl]piperazine；1-(6-chloronaphth-2-ylsulfonyl)-4-[4-(4-pyridyl)benzoyl] piperazine；[4-(6-chloronaphthalen-2-yl)sulfonylpiperazin-1-yl]-(4-pyridin-4-ylphenyl)methanone
• CAS: 207798-71-8
• 化学式: C₂₆H₂₂ClN₃O₃S
• 分子量: 491.998
• InChiKey: PSTBXECIKAJFMC-UHFFFAOYSA-N

物化性质

• 沸点：
  718.9±70.0 °C(Predicted)
• 密度：
  1.376±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  79
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[(6-chloronaphthalen-2-yl)sulfonyl]-4-[4-(pyridin-4-yl)benzoyl]piperazine 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以188 mg的产率得到4-[4-[[4-[(6-Chloronaphthalen-2-yl)sulfonyl]piperazin-1-yl]carbonyl]phenyl]pyridine N-oxide
  参考文献：
  名称：

  Sulfonamide derivatives, their production and use

  摘要：

  本发明提供了一种化合物，该化合物特异性地抑制FXa，口服给药有效，并且用作预防或治疗由血栓或梗死引起的疾病的药物是安全的。本发明的化合物是哌嗪酮的公式： 其中R1是可选地取代的烃基或可选地取代的杂环基；环A是除了被公式：的基团取代的之外的可选地取代的二价含氮杂环基： 和公式的基团： Y是可选地取代的二价烃基或可选地取代的二价杂环基；X是直接键或可选地取代的亚烷基链；Z是（1）与可选地取代的烃基取代的氨基，（2）可选地取代的亚氨基或（3）可选地取代的含氮杂环基；当X是直接键并且Z是可选地取代的6-成员含氮芳香杂环基时，Y是可选地取代的二价烃基或可选地取代的二价不饱和杂环基；或其盐。

  公开号：

  US06359134B1
• 作为产物：
  描述：

  2-氯萘 在 氯化亚砜 、 硫酸 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.5h， 生成 1-[(6-chloronaphthalen-2-yl)sulfonyl]-4-[4-(pyridin-4-yl)benzoyl]piperazine
  参考文献：
  名称：

  Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites

  摘要：

  Compound 7 was identified as the active metabolite of 6 by HPLC and mass spectral analysis. Modification of lead compound 7 by transformation of its N-oxide 6-6 biaryl ring system and fused aromatics produced a series of non-basic fxa inhibitors with excellent potency in anti-fXa and anticoagulant assays. The optimized compounds 73b and 75b showed sub to one digit micromolar anticoagulant activity (PTCT2). Particularly, anti-fXa activity was detected in plasma of rats orally administered with 1 mg/kg of compound 75b. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.04.006

文献信息

• NOVEL SULFONYL DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1104754A1

  公开（公告）日：2001-06-06

  Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.

  以下是通用公式（I）所代表的磺酰衍生物：Q1-Q2-T1-Q3-SO2-QA以及含有这些衍生物的药物（其中Q1是可选择地取代的饱和或不饱和的五元或六元环烃基团，五元或六元杂环基团等；Q2是单键，氧，硫，C1-C6烷基或类似物；QA是可选择地取代的芳基烯烃基团，杂环芳基烯烃基团或类似物；T1是羰基或类似物）。这些化合物具有强大的FXa抑制作用，并通过口服迅速产生令人满意且持久的抗血栓作用，因此可作为几乎不伴随副作用的抗凝血剂。
• Sulfonyl derivatives
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US06525042B1

  公开（公告）日：2003-02-25

  Sulfonyl derivatives represented by general formula (I), salts of the same, and solvates of both: and application of them as drugs: [wherein R1 is hydrogen, hydroxyl, nitro or the like; R2 and R3 are each independently hydrogen, halogeno or the like; R4 and R5 are each dependently hydrogen, halogeno or the like; Q1 is an optionally substituted saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group or the like; Q2 is a single bond, oxygen or the like; Q3 is, e.g., a group represented by formula (a): T1 is carbonyl or the like; and X1 and X2 are each independently methylidyne or nitrogen]. These compounds exhibit potent Fxa inhibiting activities and serve as excellent anticoagulants which speedily exert satisfactory and persistent anti-thrombotic effects through oral administration and little cause adverse effects.

  通用公式(I)表示的磺酰衍生物，其盐以及两者的溶剂化合物：以及它们作为药物的应用：[其中R1是氢、羟基、硝基或类似物；R2和R3各自独立地是氢、卤素或类似物；R4和R5各自依赖于氢、卤素或类似物；Q1是可选择取代的饱和或不饱和的5-或6-成员环烃基或类似物；Q2是单键、氧或类似物；Q3是，例如，由公式(a)表示的基团：T1是羰基或类似物；X1和X2各自独立地是甲基亚砜或氮。这些化合物表现出强大的Fxa抑制活性，并作为优秀的抗凝血剂，通过口服迅速产生令人满意且持久的抗血栓效果，并几乎不引起不良反应。
• Novel sulfonyl derivatives
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：US20040082611A1

  公开（公告）日：2004-04-29

  Described in the present invention are a sulfonyl derivative represented by the following formula (I): Q 1 -Q 2 -T 1 -Q 3 -SO 2 -Q A (I) [wherein Q 1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent; Q 2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C 1-6 alkylene group or the like; Q A represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and T 1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.

  本发明描述了一种由以下式(I)表示的磺酰基衍生物： Q1-Q2-T1-Q3-SO2-QA(I) [其中，Q1表示饱和或不饱和的5-或6-环烃基、5-或6-杂环基、二环融合环或三环融合环基，可能具有取代基；Q2表示单键、氧原子、硫原子、线性或支链的C1-6烷基等；QA表示可能具有取代基的芳基烯基或杂芳基烯基；T1表示羰基基团或类似物]，以及包含该化合物的药物。该化合物具有强烈的FXa抑制作用，口服后提供快速、充分和持久的抗血栓效果，并且具有低副作用，因此可用作优秀的抗凝剂。
• Heterocyclic derivatives
  申请人：——

  公开号：US20030195203A1

  公开（公告）日：2003-10-16

  The invention relates to heterocyclic derivatives of formula (I) A—B—X 1 —T 1 (R 2 )—L 1 —T 2 (R 3 )—X 2 —Q  (I) or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

  本发明涉及公式(I)A-B-X1-T1(R2)-L1-T2(R3)-X2-Q的杂环衍生物或其药学上可接受的盐，具有抗血栓和抗凝血特性，因此在人类或动物的治疗方法中有用。本发明还涉及制备这些杂环衍生物的过程，含有它们的制药组合物以及它们用于制造用于产生抗血栓或抗凝血效应的药物的用途。
• Remote C−H Olefination of Heterocyclic Biaryls Enabled by Reversibly Bound Templates
  作者：Luo‐Yan Liu、Zhoulong Fan、Md Emdadul Hoque、Shaoqun Qian、Guangrong Meng、Nikita Chekshin、Keita Tanaka、Jennifer X. Qiao、Kap‐Sun Yeung、Jin‐Quan Yu

  DOI：10.1002/anie.202307581

  日期：2023.9.11

  Remote C−H functionalization of heterocyclic biaryls will be of great importance in synthesis and medicinal chemistry. Through adjusting the geometric relationship of the directing atom and target C−H bonds, two new catalytic templates have been developed to enable the functionalization of the more hindered ortho‐C−H bonds of heterobiaryls bearing directing heteroatom at the meta‐ or para‐positions, affording unprecedented site‐selectivity. The use of template chaperone also overcomes product inhibition and renders the directing templates catalytic. The utility of this protocol was demonstrated by olefination of heterocyclic biaryls with various substituents, overriding conventional steric and electronic effects. These ortho‐C−H olefinated heterobiaryls are sterically hindered and can often be challenging to prepare through aryl‐aryl coupling reactions.

  摘要杂环双芳基的远程 C-H 功能化在合成和药物化学中将具有重要意义。通过调整指导原子和目标 C-H 键的几何关系，我们开发出了两种新的催化模板，可以对在元或对位上带有指导杂原子的杂环双芳基中阻碍较大的正 C-H 键进行官能化，从而获得前所未有的位点选择性。模板伴侣的使用还克服了产物抑制作用，并使定向模板具有催化作用。通过对带有各种取代基的杂环双芳基进行烯化反应，证明了这一方案的实用性，克服了传统的立体和电子效应。这些正交-C-H 烯化杂环双芳基具有立体阻碍，通常很难通过芳基-芳基偶联反应制备。